Featured

Status

Health Topics

Any Category
Diseases
Hemic and Lymphatic Diseases
Hematologic Diseases
Clear Filters

Search Clinical Trials

15 Results
Not Yet Recruiting
Heart Coherence Training on Vascular Ehlers-Danlos Syndrome Patients
Vascular Ehlers Danlos Syndrome (VEDS) is caused by pathogenic variants of the COL3A1 gene, resulting abnormal Type III collagen protein. This impacts the body's connective tissue and makes people with …
Baylor Role: Lead Sponsor
Recruiting
Oxytocin for Hypermobile Ehlers-Danlos Syndrome
This will be a single-site study to evaluate the effect of IV oxytocin on chronic pain in female adult patients with hypermobile EDS. Oxytocin secretion in the body is dynamic …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Post IVIG Medication in Children With Immune Thrombocytopenia
Immune thrombocytopenia (ITP) is the most common acquired immune cytopenia in childhood, affecting 4-6 in 100,000 children. The pathophysiology of ITP is highly complex and incompletely understood. Accepted mechanisms include …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine
The vaccine will be administered orally (by mouth) as a solution mixed with sodium bicarbonate. Approximately 10 minutes prior to receiving the vaccine, participants will take sodium bicarbonate pills to …
Baylor Role: Lead Sponsor
Completed
Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients
Study Design This is a multi-center, double blind, randomized control trial designed to assess the safety and efficacy of daily NB-UVB light for patients presenting to site hospitals over the …
Baylor Role: Collaborator
Active, Not Recruiting
Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
This is a prospective, open label, randomized, two-arm, multi-center Phase 3 trial. Patients with newly diagnosed ITP are randomized 2:1 to receive the experimental treatment, eltrombopag, or investigator's choice of …
Baylor Role: Lead Sponsor
Completed
Association of Platelet Parameters With Bleeding Severity in Children With ITP
Many children with severe immune thrombocytopenia (ITP) present with mild symptoms and their disease spontaneously resolves within 3 to 6 months. However, a subset of pediatric ITP patients experience severe …
Baylor Role: Collaborator
Recruiting
Investigation of the Genetics of Hematologic Diseases
Participants will be individuals (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder. We propose to use genomics, transcriptomics, proteomics and metabolomic analysis coupled with family linkage studies …
Baylor Role: Collaborator
Recruiting
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
Up to 390 mL (78 teaspoons) of blood will be collected from the patient on one to three occasions over a two month period. Under certain conditions related to the …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the FDA. They have not been approved in the combination for multiple myeloma or any other type of cancer. Bortezomib is …
Baylor Role: Collaborator